Studybox Research 510(k) Clinical Studies
Point-of-Care Molecular Respiratory Panel
Clinical and analytical performance to support substantial equivalence.
Studybox
510(k) Clinical Studies
Sample-to-answer molecular tests have been CLIA-waived since the middle of the last decade, and multiplexed respiratory panels on these platforms are now standard subjects for dual-submission programs. The clinical study compares each target to a cleared laboratory molecular method, which sets a high bar: the comparator is no longer a culture or antigen method the new device can easily outperform, and near-equivalence per analyte is the expectation.
The instrument changes the waiver question. For a lateral flow test the risk is misreading a line; for a molecular cartridge the risks are sample loading errors, cartridge handling, instrument placement and environmental conditions, and interpretation is done by software. Flex studies and the invalid-rate analysis therefore carry more of the waiver argument than operator interpretation does.
- Analyte
- Nucleic acid targets for influenza A, influenza B, RSV and SARS-CoV-2 (panel composition varies by device)
- Therapeutic area
- Infectious Disease
- Specimens
- Nasopharyngeal (NP) Swab, Anterior Nares (Nasal) Swab
- Intended-use settings
- urgent care, physician office, pharmacy, hospital POC, emergency department
- Operators
- Non-laboratory clinic staff in waived settings running a sample-to-answer instrument; laboratory staff for moderate-complexity claims.
- Comparator
- Typically one or more FDA-cleared laboratory molecular assays for each target, with discordant specimens tested by a second cleared molecular method or bidirectional sequencing where the protocol permits.
510(k) Studies specifics
What Changes for This Assay on This Pathway.
- Each analyte needs its own clinical performance table against a cleared molecular comparator; discordant resolution by sequencing or a second cleared assay is typically pre-specified and reported but does not replace the primary analysis.
- Analytical studies (limit of detection per target, inclusivity across strains and variants, cross-reactivity and competitive interference in co-infection) are extensive for multiplex molecular devices and are reviewed alongside the clinical data.
- If the panel includes influenza, the antigen-test special controls do not apply, but influenza inclusivity and reactivity against contemporary strains remain review topics.
Endpoints the study must support
- Positive and negative percent agreement per analyte against the molecular comparator, with 95% confidence intervals
- Invalid and error rates, including cartridge and instrument errors, by site and operator
- Performance by specimen type and age stratum, with co-infection agreement reported descriptively
Enrollment realities
Driven by the rarest analyte on the panel and by the number of waived sites running the instrument; multi-season enrollment is the norm, and instrument placement and cartridge supply at many small sites is a logistical driver of timeline. Influenza and RSV components depend on fall-to-spring circulation; SARS-CoV-2 enrollment can continue year-round, so the study typically runs continuously with analyte-specific accrual.
How Studybox runs it
Pre-Qualified Sites, Embedded Coordinators.
Our 100+ pre-qualified U.S. sites are matched to the intended-use population and setting, with Studybox coordinators embedded on site for recruitment, consent, specimen handling, and data capture. Typical activation is about four weeks. How we run 510(k) clinical studies →
Same assay, other pathways
Relevant FDA guidance
- Recommendations for Dual 510(k) and CLIA Waiver by Application Studies
- Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices
- Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program
- Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests
FAQ
Point-of-Care Molecular Respiratory Panel Study Questions.
01 Who operates the point-of-care molecular respiratory panel in a 510(k) studies study?
Non-laboratory clinic staff in waived settings running a sample-to-answer instrument; laboratory staff for moderate-complexity claims.
02 What is the comparator for a point-of-care molecular respiratory panel study?
Typically one or more FDA-cleared laboratory molecular assays for each target, with discordant specimens tested by a second cleared molecular method or bidirectional sequencing where the protocol permits.
03 What drives enrollment for a point-of-care molecular respiratory panel study?
Driven by the rarest analyte on the panel and by the number of waived sites running the instrument; multi-season enrollment is the norm, and instrument placement and cartridge supply at many small sites is a logistical driver of timeline. Influenza and RSV components depend on fall-to-spring circulation; SARS-CoV-2 enrollment can continue year-round, so the study typically runs continuously with analyte-specific accrual.
Let's talk IVD research
Planning a point-of-care molecular respiratory panel study?
Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the 510(k) studies pathway.